ReviewFrontiers in immunology2026
Identification of immunosuppressive neutrophils using multi-omics: why functional testing remains key.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymorphonuclear neutrophils (PMNs) are innate cells that may act as myeloid-derived suppressor cells (MDSCs), most often characterized by their immunosuppressive capacity towards immune cells within the tumor microenvironment. Over the last decade, many studies have tried to characterize these PMN-MDSCs. Although all human neutrophils obtain suppressive activity upon activation, specialized subsets, including low-density cells, have been proposed to exert MDSC activity without requiring prior stimulation. Single-cell RNA sequencing (scRNAseq) has created a new horizon to study possible neutrophil subsets. As such, the identification of distinct neutrophil subtypes in tumors may better characterize immunosuppressive neutrophils, in the end leading to specific targeting strategies in cancer patients. Nevertheless, scRNAseq has not yet led to a clear immunophenotypic characterization of PMN-MDSCs, and clinical relevance by functional testing is still lacking. Studies on the discrepancy in RNA abundance, protein expression and functionality in neutrophils indicate that the future for defining functional neutrophil subsets will rely on further development of single-cell techniques, like proteomics, to truly carve out neutrophil subsets and plasticity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.